S80048

具體成交價以合同協(xié)議為準

在線交流發(fā)送詢價進入商鋪同類產(chǎn)品

聯(lián)系方式：何小姐15921386130 查看聯(lián)系方式

聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息，謝謝!

公司介紹 主營產(chǎn)品

上海源葉生物科技有限公司是一家專門從事生物技術相關產(chǎn)品研發(fā)和銷售的綜合性生命科學公司,，在全體員工的不懈努力和廣大客戶的大力支持下,，公司迅速成長為一家擁有生物試劑部、實驗及醫(yī)用耗材部,、生命科學儀器部以及技術服務部等部門的高新技術企業(yè),。

展開

生物試劑,ELISA試劑盒,對照品,標準品,培養(yǎng)基,透析袋,病理科耗材,實驗室耗材

產(chǎn)品描述： Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity

靶點： PARP-2：2.1 nM (IC50)；PARP-1：3.8 nM (IC50),；V-PARP：330 nM (IC50),；TANK-1：570 nM (IC50)；PARP-3：1300 nM (IC50)

體內(nèi)研究： Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily

參考文獻：
1. Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85. 2. Bridges KA, et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5(13):5076-86. 3. Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20. 4. Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164.

溶解度： DMSO : 25 mg/mL (78.03 mM; Need ultrasonic)H2O : < 0.1 mg l (ultrasonic;warming;heat to 80°c) (insoluble)="">

配置溶液濃度參考：

1mg 5mg 10mg

1 mM 3.121 ml 15.606 ml 31.212 ml

5 mM 0.624 ml 3.121 ml 6.242 ml

10 mM 0.312 ml 1.561 ml 3.121 ml

50 mM 0.062 ml 0.312 ml 0.624 ml